Propel Bio's 10.1% passive stake adds a new large holder to MIST's shareholder base. Monitor for any future conversion to an active 13D filing or engagement, which would signal a shift in strategy. The stake size is significant for a $51M market cap company.
MIST drugs
MIST drug pipeline →Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Propel Bio Management LLC and affiliated entities filed an amended Schedule 13G disclosing beneficial ownership of 12,615,010 shares (10.1%) of Milestone Pharmaceuticals as of November 19, 2026. This is a new passive stake filing by Propel Bio, a healthcare-focused investment firm, representing a 10.1% position in the micro-cap biotech.
Key Financial Metrics
Key Facts
- Propel Bio Management LLC and affiliated entities (Leen Kawas, Richard Kayne, Propel Bio Partners LLC) filed a Schedule 13G/A disclosing 12,615,010 shares of Milestone Pharmaceuticals.
- The stake represents 10.1% of the 124,498,693 common shares outstanding as of November 13, 2026.
- 9,615,010 shares are held by private investment funds and an investment company for which Propel Bio Management and Leen Kawas provide advisory services.
- 3,000,000 shares are held by the Richard and Suzanne Kayne Living Trust, of which Richard Kayne is sole trustee.
- The filing is a new passive stake disclosure (not an amendment to a prior Propel Bio filing).
- The filing certifies the securities were not acquired for the purpose of changing or influencing control of the issuer.
Financial Impact
12,615,010 shares valued at approximately $5.2 million based on the $51M market cap and 124.5M shares outstanding (implied price ~$0.41/share).
Risk Factors
- Passive 13G filer could convert to active 13D, potentially seeking changes.
- Large concentrated ownership could lead to overhang if the investor decides to exit.
- No prior Propel Bio filing exists for comparison, so the trajectory of the stake is unknown.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G/A Filing (Primary) | 0001969764-26-000002 |
| Document: 0001969764-26-000002-index.html | 0001969764-26-000002 |
| Document: 0001969764-26-000002.txt | 0001969764-26-000002 |
Track record
13 reports on MIST
5 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +50.00% at T+20 after the Mar 20, 2026 report. 6 of 7 went positive at some point.
Filters
- Nov 20, 20261d ago SC 13G/A Neutral 4/10 Viewing Entry $0.3752 Now $0.3710 −1.12% settles Nov 30
- Nov 19, 20262d ago 3 Neutral 2/10 Entry $0.4130 Now $0.3710 −10.17% settles Nov 30
- Nov 13, 20268d ago 8-K Neutral 5/10 Entry $0.5200 to $0.3711 Now $0.3710 −28.65% ▼ −28.63% −20.08% vs SPY
- Oct 28, 202624d ago 8-K Bearish 7/10 Entry $0.7896 to $0.6925 Now $0.3710 +53.01% ▲ +12.30% +7.57% vs SPY
- Sep 3, 202611w ago 8-K Bullish 6/10 Entry $1.20 to $0.9494 Now $0.3710 −69.08% ▼ −20.88% −19.67% vs SPY
- Aug 21, 202613w ago Press Release Bullish 7/10 Entry $1.06 to $1.16 Now $0.3710 −64.83% ▲ +9.95% +9.48% vs SPY
- Aug 12, 202614w ago 8-K Bearish 6/10 Entry $1.13 to $1.08 Now $0.3710 +67.02% ▲ +4.00% +3.56% vs SPY
- May 26, 202625w ago EFFECT Bearish 6/10 Entry $1.40 to $1.32 Now $0.3710 +73.50% ▲ +5.71% +6.93% vs SPY
- May 13, 202627w ago S-3 Bearish 6/10 Entry $1.63 to $1.52 Now $0.3710 +77.24% ▲ +6.75% +6.03% vs SPY
- May 13, 202627w ago 8-K Neutral 5/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers